PL1850873T3 - Przeciwciała przeciwko tgfbeta - Google Patents
Przeciwciała przeciwko tgfbetaInfo
- Publication number
- PL1850873T3 PL1850873T3 PL06734583T PL06734583T PL1850873T3 PL 1850873 T3 PL1850873 T3 PL 1850873T3 PL 06734583 T PL06734583 T PL 06734583T PL 06734583 T PL06734583 T PL 06734583T PL 1850873 T3 PL1850873 T3 PL 1850873T3
- Authority
- PL
- Poland
- Prior art keywords
- tgfbeta
- antibodies
- Prior art date
Links
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65134305P | 2005-02-08 | 2005-02-08 | |
| PCT/US2006/004424 WO2006086469A2 (en) | 2005-02-08 | 2006-02-08 | Antibodies to tgfbeta |
| EP06734583.5A EP1850873B1 (en) | 2005-02-08 | 2006-02-08 | Antibodies to tgfbeta |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1850873T3 true PL1850873T3 (pl) | 2019-06-28 |
Family
ID=36793677
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06734583T PL1850873T3 (pl) | 2005-02-08 | 2006-02-08 | Przeciwciała przeciwko tgfbeta |
| PL18208382T PL3520815T3 (pl) | 2005-02-08 | 2006-02-08 | Przeciwciała przeciwko TGFBETA |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18208382T PL3520815T3 (pl) | 2005-02-08 | 2006-02-08 | Przeciwciała przeciwko TGFBETA |
Country Status (19)
| Country | Link |
|---|---|
| US (11) | US7723486B2 (pl) |
| EP (2) | EP1850873B1 (pl) |
| JP (5) | JP5174466B2 (pl) |
| CN (3) | CN101163502A (pl) |
| AU (1) | AU2006213875B2 (pl) |
| BR (1) | BRPI0607639B1 (pl) |
| CA (2) | CA2930677A1 (pl) |
| CY (1) | CY1121424T1 (pl) |
| DK (1) | DK1850873T3 (pl) |
| ES (2) | ES2711213T3 (pl) |
| HU (1) | HUE042689T2 (pl) |
| IL (3) | IL184995A (pl) |
| LT (1) | LT1850873T (pl) |
| MX (1) | MX2007009545A (pl) |
| PL (2) | PL1850873T3 (pl) |
| PT (2) | PT3520815T (pl) |
| SI (1) | SI1850873T1 (pl) |
| TR (1) | TR201901929T4 (pl) |
| WO (1) | WO2006086469A2 (pl) |
Families Citing this family (135)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2607424Y2 (ja) | 1990-03-16 | 2001-09-04 | 株式会社東海理化電機製作所 | ウエビング巻取装置 |
| JP2607423Y2 (ja) | 1990-03-16 | 2001-09-04 | 株式会社東海理化電機製作所 | ウエビング巻取装置 |
| JP2607425Y2 (ja) | 1990-03-16 | 2001-09-04 | 株式会社東海理化電機製作所 | ウエビング巻取装置 |
| JP2607422Y2 (ja) | 1990-03-16 | 2001-09-04 | 株式会社東海理化電機製作所 | ウエビング巻取装置 |
| US7563874B2 (en) * | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| WO2005097832A2 (en) * | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| ES2711213T3 (es) * | 2005-02-08 | 2019-04-30 | Genzyme Corp | Anticuerpos de TGFbeta |
| ES2647472T3 (es) | 2006-10-03 | 2017-12-21 | Genzyme Corporation | Anticuerpos contra TGF-BETA para uso en el tratamiento de lactantes con riesgo de desarrollar displasia broncopulmonar |
| CN101663320A (zh) | 2007-02-23 | 2010-03-03 | 先灵公司 | 工程改造的抗IL-23p19抗体 |
| SI2426144T1 (sl) | 2007-02-23 | 2019-02-28 | Merck Sharp & Dohme Corp. | Umetno proizvedena anti-IL23P19 antitelesa |
| WO2009008916A2 (en) | 2007-03-22 | 2009-01-15 | The Regents Of The University Of Californina | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| WO2010014854A2 (en) * | 2008-07-31 | 2010-02-04 | The Regents Of The University Of California | Antibodies that neutralize botulinum neurotoxins |
| UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
| MY160126A (en) | 2009-05-13 | 2017-02-28 | Genzyme Corp | Anti-human cd52 immunoglobulins |
| AU2011223710B2 (en) | 2010-03-01 | 2016-04-14 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI) |
| PL3117709T3 (pl) | 2010-03-12 | 2019-01-31 | Genzyme Corporation | Terapia skojarzona do leczenia raka piersi |
| WO2012047427A2 (en) | 2010-08-31 | 2012-04-12 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
| PH12013500411A1 (en) | 2010-09-01 | 2022-03-30 | Genzyme Corp | Treatment of myocardial infarction using tgf - beta antagonists |
| JP2014505666A (ja) | 2010-11-18 | 2014-03-06 | ザ ジェネラル ホスピタル コーポレイション | 癌治療のための降圧剤の組成物および使用 |
| CA2818548A1 (en) | 2010-11-19 | 2012-05-24 | Toshio Imai | Neutralizing anti-ccl20 antibodies |
| LT2714735T (lt) * | 2011-06-03 | 2021-12-10 | Xoma Technology Ltd. | Tgf beta specifiniai antikūnai |
| US20140308275A1 (en) | 2011-07-27 | 2014-10-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale | Methods for diagnosing and treating myhre syndrome |
| IN2014DN03049A (pl) | 2011-10-26 | 2015-05-15 | Seattle Childrens Res Inst | |
| US9782452B2 (en) | 2011-11-22 | 2017-10-10 | Cornell University | Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling |
| EP2822592B1 (en) | 2012-03-08 | 2018-08-15 | Ludwig Institute for Cancer Research Limited | Tgf- 1 specific antibodies and methods and uses thereof |
| WO2013134665A1 (en) | 2012-03-08 | 2013-09-12 | Selig Sealing Products, Inc. | Container sealing member with protected security component and removal tab |
| KR102258457B1 (ko) * | 2013-03-11 | 2021-05-31 | 젠자임 코포레이션 | 조작된 항-tgf-베타 항체 및 항원-결합 단편 |
| DK3702443T3 (da) | 2013-03-14 | 2022-04-04 | Brigham & Womens Hospital Inc | Sammensætninger og fremgangsmåder til opformering og dyrkning af epiteliale stamceller |
| PL2976359T5 (pl) * | 2013-03-20 | 2022-07-18 | Genzyme Corporation | Sposoby leczenia wrodzonej łamliwości kości |
| PL2981822T3 (pl) | 2013-05-06 | 2021-07-12 | Scholar Rock, Inc. | Kompozycje i sposoby modulacji czynnika wzrostu |
| HK1225740A1 (zh) | 2013-08-22 | 2017-09-15 | Acceleron Pharma Inc. | TGF-β受体II型变体及其用途 |
| KR102360315B1 (ko) * | 2014-05-16 | 2022-02-08 | 웰헤드 바이오로지컬 테크놀로지 코포레이션. | 신장 섬유증을 억제하기 위한 진세노사이드 m1의 용도 |
| KR102493376B1 (ko) | 2014-09-03 | 2023-01-27 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 청력 손실의 치료를 위해 내이 털세포를 생성하기 위한 조성물, 시스템, 및 방법 |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| CA2964367C (en) | 2014-10-14 | 2024-01-30 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| WO2016100233A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| HUE070137T2 (hu) | 2014-12-15 | 2025-05-28 | Univ California | CD19-re és CD20-ra érzékeny bispecifikus VAGY-kapu kiméra antigénreceptor |
| HK1245134A1 (zh) | 2015-01-14 | 2018-08-24 | The Brigham And Women's Hospital, Inc. | 用抗lap单克隆抗体治疗癌症 |
| CN108136001B (zh) | 2015-04-03 | 2022-07-29 | 佐马技术有限公司 | 使用TGF-β抑制剂和PD-1抑制剂治疗癌症 |
| EP3307772B1 (en) | 2015-06-12 | 2020-09-09 | Ludwig Institute For Cancer Research Limited | Tgf-beta 3 specific antibodies and methods and uses thereof |
| TW201718010A (zh) * | 2015-06-19 | 2017-06-01 | 健臻公司 | 治療原發性局部節段性腎小球硬化症之方法 |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| WO2017019896A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| EP3331550B1 (en) | 2015-08-04 | 2022-11-02 | Acceleron Pharma Inc. | Composition for treating myeloproliferative disorders |
| HRP20230239T1 (hr) * | 2015-10-30 | 2023-04-14 | The Regents Of The University Of California | Polipeptidi koji reagiraju na transformirajući faktor rasta – beta i postupci za njihovu upotrebu |
| WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| EP3389720A1 (en) | 2015-12-18 | 2018-10-24 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
| JP2019506153A (ja) | 2016-01-08 | 2019-03-07 | マサチューセッツ インスティテュート オブ テクノロジー | 分化した腸内分泌細胞およびインスリン産生細胞の作製 |
| WO2017127390A1 (en) * | 2016-01-21 | 2017-07-27 | The Scripps Research Institute | Synthetic opioid vaccine |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| BR112018068340A2 (pt) | 2016-03-11 | 2019-01-15 | Scholar Rock Inc | imunoglobulinas de ligação ao tgfss1 e usos destas |
| AU2017268234A1 (en) | 2016-05-17 | 2018-12-13 | Genentech, Inc. | Stromal gene signatures for diagnosis and use in immunotherapy |
| GB201610044D0 (en) * | 2016-06-08 | 2016-07-20 | Ucb Biopharma Sprl | Antibodies |
| AU2017310344A1 (en) * | 2016-08-11 | 2019-03-07 | Precithera, Inc. | TGF-β antagonist conjugates |
| US11701384B2 (en) | 2016-09-02 | 2023-07-18 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
| WO2018043734A1 (en) * | 2016-09-05 | 2018-03-08 | Chugai Seiyaku Kabushiki Kaisha | Anti-tgf-beta 1 antibodies and methods of use |
| US10610104B2 (en) | 2016-12-07 | 2020-04-07 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| SG10201910821XA (en) | 2016-12-30 | 2020-01-30 | Frequency Therapeutics Inc | 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
| KR20190098255A (ko) | 2017-01-06 | 2019-08-21 | 스칼러 락, 인크. | 이소형-특이적, 콘텍스트-허용성 TGFβ1 억제제 및 그의 용도 |
| EA201991729A1 (ru) | 2017-01-20 | 2019-12-30 | Санофи | Антитела к tgf-бета и их применение |
| TWI787230B (zh) | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗ＴＧＦ-β抗體及其用途 |
| TW202421659A (zh) | 2017-01-20 | 2024-06-01 | 美商健臻公司 | 骨靶向抗體 |
| EP4241848A3 (en) | 2017-05-04 | 2023-11-01 | Acceleron Pharma Inc. | Tgf-beta receptor type ii fusion proteins and uses thereof |
| US20200172628A1 (en) | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| MY204117A (en) | 2017-06-22 | 2024-08-08 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | ANTI-LAP ANTIBODIES AND USES THEREOF |
| CA3077664A1 (en) | 2017-11-06 | 2019-05-09 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| CA3081602A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Combination therapies |
| AU2018375738A1 (en) | 2017-11-30 | 2020-06-11 | Novartis Ag | BCMA-targeting chimeric antigen receptor, and uses thereof |
| JP7319992B2 (ja) | 2018-03-09 | 2023-08-02 | アジェナス インコーポレイテッド | 抗ｃｄ７３抗体およびそれらの使用方法 |
| US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| TWI869346B (zh) | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| CN118459594A (zh) | 2018-06-01 | 2024-08-09 | 诺华股份有限公司 | 针对bcma的结合分子及其用途 |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| AU2019301283B2 (en) * | 2018-07-10 | 2024-12-19 | Sanofi | Combination therapies against cancer targeting CD38 and TGF-beta |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| WO2020014473A1 (en) | 2018-07-11 | 2020-01-16 | Scholar Rock, Inc. | TGFβ1 INHIBITORS AND USE THEREOF |
| LT3677278T (lt) | 2018-07-11 | 2022-01-10 | Scholar Rock, Inc. | Izoformoms selektyvūs tgfbeta1 inhibitoriai ir jų panaudojimas |
| EP3820508A1 (en) | 2018-07-11 | 2021-05-19 | Scholar Rock, Inc. | High-affinity, isoform-selective tgf?1 inhibitors and use thereof |
| WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
| US11617745B2 (en) | 2018-08-17 | 2023-04-04 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating FOXO |
| EP3837352A1 (en) | 2018-08-17 | 2021-06-23 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating jag-1 |
| KR20250160211A (ko) | 2018-08-30 | 2025-11-11 | 이뮤니티바이오, 인크. | 다중-사슬 키메라 폴리펩타이드 및 이의 용도 |
| CN113365663B (zh) | 2018-08-30 | 2025-11-21 | 免疫生物公司 | 单链嵌合多肽和其用途 |
| JP2022504839A (ja) | 2018-10-10 | 2022-01-13 | ティロス・セラピューティクス・インコーポレイテッド | 抗ｌａｐ抗体変異体及びその使用 |
| AU2019375036A1 (en) | 2018-11-05 | 2021-06-03 | Centre Hospitalier Universitaire Vaudois | Humanized and variant TGF-beta1 specific antibodies and methods and uses thereof |
| CA3118027A1 (en) | 2018-11-05 | 2020-05-14 | Ludwig Institute For Cancer Research Ltd. | Humanized and variant tgf-.beta.3 specific antibodies and methods and uses thereof |
| WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| KR20210106437A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물 |
| TW202043267A (zh) | 2019-01-30 | 2020-12-01 | 美商供石公司 | TGFβ之LTBP複合物專一性抑制劑及其用途 |
| AU2020222345B2 (en) | 2019-02-15 | 2022-11-17 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US12479817B2 (en) | 2019-02-15 | 2025-11-25 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| JP2022527972A (ja) | 2019-04-02 | 2022-06-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 前悪性病変を有する患者において癌を予測及び予防する方法 |
| US11738052B2 (en) | 2019-06-21 | 2023-08-29 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| CA3152371A1 (en) * | 2019-08-01 | 2021-02-04 | Vaccinex, Inc. | Combined inhibition of semaphorin-4d and tgf.beta. and compositions therefor |
| US20220348651A1 (en) | 2019-09-18 | 2022-11-03 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與ｅｎｔｐｄ２抗體之組合療法 |
| WO2021081258A1 (en) | 2019-10-23 | 2021-04-29 | Cue Biopharma, Inc. | TGF-β POLYPEPTIDES |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| JP2023506958A (ja) | 2019-12-20 | 2023-02-20 | ノバルティス アーゲー | 骨髄線維症および骨髄異形成症候群を処置するための、デシタビンまたは抗ｐｄ－１抗体スパルタリズマブを伴うかまたは伴わない抗ｔｉｍ－３抗体ｍｂｇ４５３および抗ｔｇｆ－ベータ抗体ｎｉｓ７９３の組合せ |
| WO2021142427A1 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock, Inc. | TGFβ INHIBITORS AND USE THEREOF |
| WO2021163298A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| KR20220140535A (ko) | 2020-02-11 | 2022-10-18 | 에이치씨더블유 바이올로직스, 인크. | 크로마토그래피 수지 및 이의 용도 |
| CA3169231A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
| US11919948B2 (en) | 2020-03-19 | 2024-03-05 | Genentech, Inc. | Isoform-selective anti-TGFβ antibodies and methods of use |
| JP7734693B2 (ja) | 2020-04-29 | 2025-09-05 | イミュニティーバイオ インコーポレイテッド | 抗ｃｄ２６タンパク質及びそれらの使用法 |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP4204020A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
| WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| US20240025993A1 (en) | 2020-11-06 | 2024-01-25 | Novartis Ag | Cd19 binding molecules and uses thereof |
| MX2023005565A (es) * | 2020-11-11 | 2024-02-23 | Hq Han | Antagonistas bifuncionales de activina/tgf-beta y rankl y usos de los mismos. |
| WO2022115611A1 (en) | 2020-11-25 | 2022-06-02 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
| US20240141060A1 (en) | 2021-01-29 | 2024-05-02 | Novartis Ag | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
| US20240226295A9 (en) | 2021-02-15 | 2024-07-11 | Takeda Pharmaceutical Company Limited | Cell therapy compositions and methods for modulating tgf-b signaling |
| EP4294827A1 (en) | 2021-02-19 | 2023-12-27 | Theripion, Inc. | Paraoxonase fusion polypeptides and related compositions and methods |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| CN112940119B (zh) * | 2021-04-26 | 2022-05-20 | 北京芳渟阳生生物科技有限公司 | 一种单克隆抗体及其与间充质干细胞外泌体的联合应用 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| JP2024532760A (ja) | 2021-08-11 | 2024-09-10 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 多重鎖キメラポリペプチド及び肝疾患の治療におけるその使用 |
| WO2023080900A1 (en) | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
| KR20250004747A (ko) | 2022-04-13 | 2025-01-08 | 이뮤니티바이오, 인크. | 생체 시계 유전자 장애의 치료에 사용하기 위한 다중-사슬 키메라 폴리펩티드 |
| JP2025513831A (ja) | 2022-04-13 | 2025-04-30 | イミュニティバイオ，インコーポレーテッド | 神経炎症性障害の処置における使用のための多重鎖キメラポリペプチド |
| TWI866210B (zh) | 2022-05-17 | 2024-12-11 | 大陸商蘇州創勝醫藥集團有限公司 | 雙功能蛋白質及其製劑和用途 |
| WO2024077095A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating bladder cancer |
| EP4599088A1 (en) | 2022-10-05 | 2025-08-13 | Genentech, Inc. | Methods and compositions for classifying and treating lung cancer |
| CN120418286A (zh) * | 2023-01-09 | 2025-08-01 | 北京拓界生物医药科技有限公司 | TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途 |
| EP4509522A1 (en) | 2023-08-16 | 2025-02-19 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | A tgfbeta switch receptor, a nucleic acid encoding it, cells and pharmaceutical compositions comprising the same |
| WO2025058919A1 (en) * | 2023-09-12 | 2025-03-20 | Lyell Immunopharma, Inc. | Bispecific chimeric antigen receptors and use thereof |
| WO2025140212A1 (en) * | 2023-12-26 | 2025-07-03 | Laekna Therapeutics Shanghai Co., Ltd. | Multispecific binding agents comprising anti-fibroblast activation protein (fap) antibodies and one or more monovalent ligand traps and uses thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2056642B (en) | 1979-08-08 | 1983-05-11 | Dawson Int | Radio frequency drying of textile material |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5571714A (en) * | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| US20040028682A1 (en) * | 1989-09-29 | 2004-02-12 | Border Wayne A. | Inhibiting transforming growth factor beta to prevent accumulation of extracellular matrix |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0561921A1 (en) | 1990-12-10 | 1993-09-29 | Panama Engineering Pty Limited | Fork-lift attachment |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| US5269388A (en) | 1991-11-12 | 1993-12-14 | Stress-Tek, Inc. | Weighing bed |
| US5543143A (en) * | 1992-03-06 | 1996-08-06 | Corixa Corporation | Method for activating macrophages/monocytes |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US5824655A (en) | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| BRPI9707379C8 (pt) | 1996-02-09 | 2017-12-12 | Abbott Biotech Ltd | composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado. |
| KR100487456B1 (ko) | 1996-03-10 | 2005-11-25 | 메이지 데어리즈 코포레이션 | 알레르기질환에대한펩티드면역치료제 |
| AU775076B2 (en) | 1998-12-10 | 2004-07-15 | Bristol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
| EP2319870A3 (en) | 1999-03-25 | 2011-10-26 | Abbott GmbH & Co. KG | Human antibodies that bind human IL-12 and methods for producing |
| US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| ATE414151T1 (de) | 2000-03-03 | 2008-11-15 | Cambridge Antibody Tech | Antikörper gegen eotaxin und deren verwendung |
| US20030224501A1 (en) * | 2000-03-17 | 2003-12-04 | Young Paul E. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
| BR0115983A (pt) * | 2000-12-06 | 2003-12-30 | Applied Research Systems | Uso de sarp-1 para o tratamento e/ou prevenção de escleroderma |
| WO2004018430A1 (ja) * | 2002-08-23 | 2004-03-04 | Kirin Beer Kabushiki Kaisha | ＴＧＦβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
| JP2006525362A (ja) * | 2003-04-30 | 2006-11-09 | ジェンザイム コーポレーション | 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用 |
| EP1646655A2 (en) | 2003-07-09 | 2006-04-19 | Eli Lilly And Company | Tgf-beta1 ligands |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| JP2005112812A (ja) * | 2003-10-09 | 2005-04-28 | Zeria Pharmaceut Co Ltd | リン酸化部位特異的抗体及びそれを用いたスクリーニング方法 |
| DK1702059T3 (da) | 2003-12-09 | 2013-03-04 | Novozymes Inc | Fremgangsmåder til eliminering og reduktion af ekspression af gener i filamentøse svampestammer |
| WO2005097832A2 (en) * | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| KR100749566B1 (ko) * | 2004-04-21 | 2007-08-16 | 이화여자대학교 산학협력단 | Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체 |
| ES2711213T3 (es) * | 2005-02-08 | 2019-04-30 | Genzyme Corp | Anticuerpos de TGFbeta |
| ITMI20110376A1 (it) | 2011-03-10 | 2012-09-11 | Wilic Sarl | Aerogeneratore raffreddato a fluido |
| DE102011078333A1 (de) | 2011-06-29 | 2013-01-03 | Siemens Aktiengesellschaft | Überspannungsableiter |
-
2006
- 2006-02-08 ES ES06734583T patent/ES2711213T3/es active Active
- 2006-02-08 HU HUE06734583A patent/HUE042689T2/hu unknown
- 2006-02-08 BR BRPI0607639-4A patent/BRPI0607639B1/pt active IP Right Grant
- 2006-02-08 EP EP06734583.5A patent/EP1850873B1/en active Active
- 2006-02-08 EP EP18208382.4A patent/EP3520815B1/en active Active
- 2006-02-08 JP JP2007554339A patent/JP5174466B2/ja active Active
- 2006-02-08 LT LTEP06734583.5T patent/LT1850873T/lt unknown
- 2006-02-08 WO PCT/US2006/004424 patent/WO2006086469A2/en not_active Ceased
- 2006-02-08 CN CNA2006800088389A patent/CN101163502A/zh active Pending
- 2006-02-08 AU AU2006213875A patent/AU2006213875B2/en active Active
- 2006-02-08 PT PT182083824T patent/PT3520815T/pt unknown
- 2006-02-08 CN CN201410331821.3A patent/CN104177497B/zh active Active
- 2006-02-08 MX MX2007009545A patent/MX2007009545A/es active IP Right Grant
- 2006-02-08 TR TR2019/01929T patent/TR201901929T4/tr unknown
- 2006-02-08 US US11/350,906 patent/US7723486B2/en active Active
- 2006-02-08 PL PL06734583T patent/PL1850873T3/pl unknown
- 2006-02-08 DK DK06734583.5T patent/DK1850873T3/en active
- 2006-02-08 PL PL18208382T patent/PL3520815T3/pl unknown
- 2006-02-08 PT PT06734583T patent/PT1850873T/pt unknown
- 2006-02-08 CA CA2930677A patent/CA2930677A1/en not_active Abandoned
- 2006-02-08 CN CN201410332384.7A patent/CN104151427B/zh active Active
- 2006-02-08 ES ES18208382T patent/ES2905923T3/es active Active
- 2006-02-08 CA CA2597098A patent/CA2597098C/en active Active
- 2006-02-08 SI SI200632315T patent/SI1850873T1/sl unknown
-
2007
- 2007-01-30 US US11/700,684 patent/US20070264255A1/en not_active Abandoned
- 2007-01-30 US US11/700,711 patent/US20070134246A1/en not_active Abandoned
- 2007-08-02 IL IL184995A patent/IL184995A/en active IP Right Grant
-
2010
- 2010-03-15 US US12/724,347 patent/US8383780B2/en active Active
-
2012
- 2012-08-16 JP JP2012180580A patent/JP5726140B2/ja active Active
- 2012-09-13 US US13/615,388 patent/US8591901B2/en active Active
-
2013
- 2013-04-14 IL IL225752A patent/IL225752A/en active IP Right Grant
- 2013-10-21 US US14/059,241 patent/US9090685B2/en active Active
-
2014
- 2014-09-22 JP JP2014192304A patent/JP6005703B2/ja active Active
-
2015
- 2015-04-09 US US14/682,975 patent/US9481726B2/en active Active
-
2016
- 2016-03-30 JP JP2016067713A patent/JP6341945B2/ja active Active
- 2016-09-28 US US15/278,819 patent/US10174108B2/en active Active
-
2017
- 2017-08-01 JP JP2017148818A patent/JP6463807B2/ja active Active
- 2017-10-16 IL IL255078A patent/IL255078B/en active IP Right Grant
-
2018
- 2018-11-21 US US16/197,802 patent/US10781252B2/en active Active
-
2019
- 2019-02-26 CY CY20191100235T patent/CY1121424T1/el unknown
-
2020
- 2020-08-19 US US16/997,365 patent/US20210061897A1/en not_active Abandoned
-
2022
- 2022-09-16 US US17/932,950 patent/US20230078449A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT1850873T (lt) | Antikūnas prieš tgf beta | |
| IL189599A0 (en) | Methods to enhance chemotherapy | |
| IL191340A (en) | Monoclonal antibodies against e8o | |
| IL186739A0 (en) | Antibodies to myostatin | |
| ZA200900395B (en) | Antibodies directed to +-Vß6 and uses thereof | |
| IL187106A (en) | Sclerostin binds antibody | |
| IL190472A0 (en) | Anti-glypican-3 antibody | |
| IL192266A0 (en) | Anti-ilt7 antibody | |
| IL185366A0 (en) | Antibody | |
| EP2125890A4 (en) | ANTIBODIES AGAINST PHOSPHORYLATED IRAQ4 | |
| PT2011869E (pt) | Novo anticorpo anti-cd98 | |
| GB0517487D0 (en) | Antibodies | |
| EP1869192A4 (en) | FRAME MIXTURE OF ANTIBODIES | |
| IL172276A0 (en) | Cross-reference to related application | |
| EP1896047A4 (en) | ANTI-GFRALPHA3 ANTIBODIES | |
| GB0505489D0 (en) | Antibodies | |
| ZA200804254B (en) | Human monoclonal antibodies to O8E | |
| GB0512278D0 (en) | Antibodies | |
| GB0505054D0 (en) | Antibodies | |
| GB0517718D0 (en) | Further improvement to brikmat | |
| GB2423802B (en) | Improvements relating to vacuum-brake-boosters | |
| GB0500847D0 (en) | Claims to be made | |
| GB0519883D0 (en) | Antibodies | |
| GB0413163D0 (en) | Improvements to signware | |
| GB0500400D0 (en) | Antibody |